Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Am J Physiol Endocrinol Metab ; 289(3): E366-72, 2005 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-15797986

RESUMO

Phosphorylase is regulated by a number of small-molecular-weight effectors that bind to three sites on the enzyme. Recently, a fourth site referred to as the indole-inhibitor site has been identified. Synthetic compounds bind to the site and inhibit activity. However, the effects of these compounds in the presence of other endogenous effectors are unknown. We have determined the effects of four indole derivative glycogen phosphorylase inhibitors (GPI) on recombinant human liver glycogen phosphorylase a activity. The GPIs tested were all potent inhibitors. However, the endogenous inhibitors (glucose, ADP, ATP, fructose 1-phosphate, glucose 6-phosphate, UDP-glucose) and the activator (AMP) markedly reduced the inhibitory effect of GPIs. Consistent with these in vitro findings, the IC50 for the inhibition of glycogenolysis in cells and the liver drug concentration associated with glucose-lowering activity in diabetic ob/ob mice in vivo were also significantly higher than those determined in in vitro enzyme assays. The inhibitory effect of indole-site effectors is modulated by endogenous small-molecular-weight effectors of phosphorylase a activity. However, at higher concentrations (10-30 microM), the GPI effect was dominant and resulted in inhibition of phosphorylase a activity irrespective of the presence or absence of the other modulators of the enzyme.


Assuntos
Glicemia/metabolismo , Hiperglicemia/tratamento farmacológico , Indóis/farmacologia , Fígado/enzimologia , Fosforilase a/antagonistas & inibidores , Fosforilase a/metabolismo , Difosfato de Adenosina/metabolismo , Trifosfato de Adenosina/metabolismo , Amidas/farmacologia , Animais , Linhagem Celular , Relação Dose-Resposta a Droga , Ativação Enzimática/efeitos dos fármacos , Ativação Enzimática/fisiologia , Frutosefosfatos/metabolismo , Glucofosfatos/metabolismo , Glicogênio/metabolismo , Humanos , Hiperglicemia/metabolismo , Hipoglicemia/induzido quimicamente , Hipoglicemia/metabolismo , Masculino , Fosforilase b/antagonistas & inibidores , Fosforilase b/metabolismo , Ratos , Ratos Sprague-Dawley , Uridina Difosfato Glucose/metabolismo
2.
Bioorg Med Chem Lett ; 15(2): 459-65, 2005 Jan 17.
Artigo em Inglês | MEDLINE | ID: mdl-15603973

RESUMO

The synthesis, in vitro, and in vivo biological characterization of a series of achiral 5-chloroindoloyl glycine amide inhibitors of human liver glycogen phosphorylase A are described. Improved potency over previously reported compounds in cellular and in vivo assays was observed. The allosteric binding site of these compounds was shown by X-ray crystallography to be the same as that reported previously for 5-chloroindoloyl norstatine amides.


Assuntos
Amidas/síntese química , Inibidores Enzimáticos/síntese química , Glicogênio Fosforilase/antagonistas & inibidores , Indóis/síntese química , Sítio Alostérico , Amidas/farmacologia , Aminocaproatos/química , Aminocaproatos/farmacologia , Cristalografia por Raios X , Inibidores Enzimáticos/farmacologia , Glicina/química , Glicina/farmacologia , Glicogênio Fosforilase/metabolismo , Humanos , Indóis/química , Indóis/farmacologia , Fígado/enzimologia , Fígado/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA